应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
RVNC Revance Therapeutics Inc
交易中 11-21 13:38:57 EST
3.87
+0.07
+1.71%
最高
3.88
最低
3.76
成交量
25.59万
今开
3.77
昨收
3.80
日振幅
3.16%
总市值
4.05亿
流通市值
3.73亿
总股本
1.05亿
成交额
98.14万
换手率
0.27%
流通股本
9,654万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Revance Therapeutics, Inc.盘中异动 早盘股价大跌5.01%报3.79美元
市场透视 · 11-19 22:36
Revance Therapeutics, Inc.盘中异动 早盘股价大跌5.01%报3.79美元
Revance Therapeutics, Inc.盘中异动 早盘股价大涨5.27%报3.90美元
市场透视 · 11-11
Revance Therapeutics, Inc.盘中异动 早盘股价大涨5.27%报3.90美元
Revance Therapeutics, Inc.2024财年第三财季实现净利润-38.12百万美元,同比增加72.96%
市场透视 · 11-11
Revance Therapeutics, Inc.2024财年第三财季实现净利润-38.12百万美元,同比增加72.96%
异动解读 | Revance撤回全年预期并推迟并购交易 盘中重挫逾26%
异动解读 · 11-08
异动解读 | Revance撤回全年预期并推迟并购交易 盘中重挫逾26%
Revance Therapeutics, Inc.股价重挫26.04% 市值跌1.17亿美元
市场透视 · 11-08
Revance Therapeutics, Inc.股价重挫26.04% 市值跌1.17亿美元
异动解读 | Revance 盘前重挫逾 15%,两大负面消息引发市场担忧
异动解读 · 11-08
异动解读 | Revance 盘前重挫逾 15%,两大负面消息引发市场担忧
异动解读 | 抗皱剂公司Revance因撤回年度预测和推迟并购交易导致股价重挫
异动解读 · 11-08
异动解读 | 抗皱剂公司Revance因撤回年度预测和推迟并购交易导致股价重挫
BUZZ-Revance 因公司撤回年度预测、延长要约收购截止日期而下跌
路透中文 · 11-08
BUZZ-Revance 因公司撤回年度预测、延长要约收购截止日期而下跌
Revance Therapeutics, Inc.盘中异动 大幅下挫5.08%
市场透视 · 11-01
Revance Therapeutics, Inc.盘中异动 大幅下挫5.08%
BUZZ--美国股票走势-Monte Rosa、EyePoint Pharma、Shake Shack
Reuters · 10-29
BUZZ--美国股票走势-Monte Rosa、EyePoint Pharma、Shake Shack
Revance Therapeutics, Inc.股价拉升27.87% 市值涨1.75亿美元
市场透视 · 10-28
Revance Therapeutics, Inc.股价拉升27.87% 市值涨1.75亿美元
BUZZ-Revance 因与 Teoxane 签订独家分销协议而飙升
Reuters · 10-28
BUZZ-Revance 因与 Teoxane 签订独家分销协议而飙升
Revance Therapeutics, Inc.盘中异动 早盘急速下跌5.09%
市场透视 · 10-25
Revance Therapeutics, Inc.盘中异动 早盘急速下跌5.09%
Revance Therapeutics, Inc.盘中异动 临近午盘股价大涨5.03%报5.64美元
市场透视 · 09-24
Revance Therapeutics, Inc.盘中异动 临近午盘股价大涨5.03%报5.64美元
Revance Therapeutics, Inc.股价重挫10.33% 市值跌5606.93万美元
市场透视 · 09-23
Revance Therapeutics, Inc.股价重挫10.33% 市值跌5606.93万美元
Revance Therapeutics, Inc.2024财年第二财季实现净利润-37.47百万美元,同比增加44.34%
自选股智能写手 · 08-18
Revance Therapeutics, Inc.2024财年第二财季实现净利润-37.47百万美元,同比增加44.34%
BUZZ--美国股票走势-Revance, B Riley, Neuronetics
Reuters · 08-13
BUZZ--美国股票走势-Revance, B Riley, Neuronetics
BUZZ--美国股票走势-Revance, B Riley, Neuronetics
Reuters · 08-13
BUZZ--美国股票走势-Revance, B Riley, Neuronetics
今日优惠-合并与收购
Reuters · 08-12
今日优惠-合并与收购
Revance Therapeutics, Inc.盘中异动 股价大涨85.55%
自选股智能写手 · 08-12
Revance Therapeutics, Inc.盘中异动 股价大涨85.55%
加载更多
公司概况
公司名称:
Revance Therapeutics Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Revance Therapeutics, Inc.于1999年8月10日成立于特拉华公司,当时名为Essentia Biosystems公司。公司是一家处于专业临床阶段的生物制药公司,专注于开发、制造和商业化用以美容和治疗的异常型肉毒杆菌毒素产品。肉毒杆菌毒素是一种良好的蛋白,目前广泛应用于美容和治疗适应症,在美国和其他国家是一个数十亿美元的市场。目前批准和商用的肉毒杆菌毒素都是注入型的。RT001, 公司的主要候选产品,是a型肉毒毒素局部配方,相对于现有注射肉毒杆菌毒素市场产品,被认为有显著的优势。公司的第二个候选产品RT002,是一种新型注射肉毒杆菌毒素类型的配方,其设计更有针对性,与其他肉毒杆菌毒素注射产品相比,更持久。这些候选产品,结合了公司的净化肉毒杆菌毒素和专有肽输送系统。公司对其两个候选产品,在全球拥有发行权利。
发行价格:
--
{"stockData":{"symbol":"RVNC","market":"US","secType":"STK","nameCN":"Revance Therapeutics Inc","latestPrice":3.865,"timestamp":1732214328323,"preClose":3.8,"halted":0,"volume":255894,"delay":0,"floatShares":96543629,"shares":104902388,"eps":-1.906672,"marketStatus":"交易中","marketStatusCode":2,"change":0.065,"latestTime":"11-21 13:38:57 EST","open":3.77,"high":3.88,"low":3.76,"amount":981403.901118,"amplitude":0.031579,"askPrice":3.87,"askSize":799,"bidPrice":3.86,"bidSize":1055,"shortable":3,"etf":0,"ttmEps":-1.906672,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732222800000},"adr":0,"listingDate":1391662800000,"adjPreClose":3.8,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":3.7001,"preClose":3.8,"latestTime":"09:26 EST","volume":36,"amount":135.3980988,"timestamp":1732199180026},"postHourTrading":{"tag":"盘后","latestPrice":3.83,"preClose":3.8,"latestTime":"17:25 EST","volume":14710,"amount":55914.61,"timestamp":1732141510130},"volumeRatio":0.267964,"impliedVol":3.3742,"impliedVolPercentile":0.9603},"requestUrl":"/m/hq/s/RVNC","defaultTab":"news","newsList":[{"id":"2484923380","title":"Revance Therapeutics, Inc.盘中异动 早盘股价大跌5.01%报3.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484923380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484923380?lang=zh_cn&edition=full","pubTime":"2024-11-19 22:36","pubTimestamp":1732026977,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日22时36分,Revance Therapeutics, Inc.股票出现异动,股价大幅跳水5.01%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.59%。其相关个股中,Psyence Biomedical Ltd C/Wts 25/01/2029、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Exicure, Inc.涨幅较大,Tff Pharmaceuticals, Inc.、Hcw Biologics Inc.、Exicure, Inc.较为活跃,换手率分别为645.07%、81.68%、66.38%,振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Tff Pharmaceuticals, Inc.、Sab Biotherapeutics Inc C/Wts 22/10/2026 ,振幅分别为52.14%、32.55%、28.79%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922361798e43803&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922361798e43803&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RVNC","LU0053671581.USD","BK4007","LENZ","BK4585","BK4588"],"gpt_icon":0},{"id":"2482787738","title":"Revance Therapeutics, Inc.盘中异动 早盘股价大涨5.27%报3.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482787738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482787738?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:43","pubTimestamp":1731336222,"startTime":"0","endTime":"0","summary":"北京时间2024年11月11日22时43分,Revance Therapeutics, Inc.股票出现异动,股价急速拉升5.27%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.10%。其相关个股中,Cero Therapeutics Holdings, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Pyxis Oncology, Inc.涨幅较大,Revelation Biosciences, Inc.、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃,换手率分别为432.55%、187.45%、90.64%,振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Revelation Biosciences, Inc.,振幅分别为76.29%、31.82%、22.93%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111224342a22ceb01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111224342a22ceb01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVNC","LU0053671581.USD","BK4585","BK4588","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2482626739","title":"Revance Therapeutics, Inc.2024财年第三财季实现净利润-38.12百万美元,同比增加72.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482626739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482626739?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:00","pubTimestamp":1731254421,"startTime":"0","endTime":"0","summary":"11月11日,Revance Therapeutics, Inc.公布财报,公告显示公司2024财年第三财季净利润为-38.12百万美元,同比增加72.96%;其中营业收入为59.88百万美元,同比增加5.46%,每股基本收益为-0.37美元。从资产负债表来看,Revance Therapeutics, Inc.总负债6.25亿美元,其中短期债务27.36百万美元,资产负债比为0.74,流动比率为0.05。机构评级:截至2024年11月11日,当前有7家机构对Revance Therapeutics, Inc.目标价做出预测,其中目标均价为9.23美元,其中最低目标价为6.00美元,最高目标价为25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000030abb36203&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000030abb36203&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVNC","LENZ"],"gpt_icon":0},{"id":"1174788842","title":"异动解读 | Revance撤回全年预期并推迟并购交易 盘中重挫逾26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174788842","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174788842?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:35","pubTimestamp":1731076501,"startTime":"0","endTime":"0","summary":"美国生物科技公司Revance Therapeutics Inc今日盘中股价大跌26.82%,收于3.56美元,引发市场广泛关注。首先,Revance宣布撤回之前提供的全年业绩指引,不再给出任何前瞻性预测。另一方面,Revance与Crown Labs的合并交易也出现延迟,双方同意将要约收购的最后期限延长至11月12日。该笔并购交易拖延较久,更令投资者对其能否最终完成产生重大疑虑,进一步打击了市场对Revance前景的信心。值得注意的是,Revance股价在过去一段时间内已累积下跌超过32%,持续的下滑走势更为今日重挫火上浇油。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVNC"],"gpt_icon":0},{"id":"2481104885","title":"Revance Therapeutics, Inc.股价重挫26.04% 市值跌1.17亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481104885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481104885?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:31","pubTimestamp":1731076296,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日22时31分,Revance Therapeutics, Inc.股票出现波动,股价急速下跌26.04%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.56%。其相关个股中,Fortrea Holdings Inc.、Poseida Therapeutics, Inc.、Tc Biopharm Plc C/Wts 10/02/2028 涨幅较大,Elevai Labs, Inc.、Matinas Biopharma Holdings, Inc.、Lipella Pharmaceuticals Inc.较为活跃,换手率分别为371.72%、16.25%、13.59%,振幅较大的相关个股有Anebulo Pharmaceuticals, Inc.、Cardiff Oncology, Inc.、Sab Biotherapeutics, Inc.,振幅分别为14.96%、13.69%、11.62%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822313695bdeed7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822313695bdeed7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4588","RVNC","BK4139","LENZ","LU0053671581.USD","BK4585"],"gpt_icon":0},{"id":"1142313771","title":"异动解读 | Revance 盘前重挫逾 15%,两大负面消息引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1142313771","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142313771?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:08","pubTimestamp":1731056903,"startTime":"0","endTime":"0","summary":"美国生物科技公司 Revance Therapeutics Inc 周三盘前股价大跌 15.57%,引发市场广泛关注。这一重挫主要源于公司相继宣布两大消息,令投资者对其未来增长前景的担忧加剧。首先,Revance 撤回了之前给出的全年业绩指引,不再提供任何前瞻性预测。此举无疑加剧了投资者对 Revance 未来增长能力的疑虑。值得注意的是,Revance 股价在过去一段时间内已累积下跌超过 32%,持续的下滑走势更为此次盘前重挫火上浇油。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVNC"],"gpt_icon":0},{"id":"1179584697","title":"异动解读 | 抗皱剂公司Revance因撤回年度预测和推迟并购交易导致股价重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1179584697","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179584697?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:37","pubTimestamp":1731055042,"startTime":"0","endTime":"0","summary":"Revance Therapeutics Inc ,这家致力于开发新型抗皱注射剂的公司,周二夜盘股价大跌16.9%,收于4.80美元,主要受两大消息影响。此次预测指引的撤回使RVNC在业内地位面临挑战。另一方面,RVNC与Crown Labs的合并交易也出现延迟。双方同意将要约收购的最后期限延长至11月12日。长期拖延的并购交易令人质疑交易能否最终完成,进一步打击了投资者的信心。值得注意的是,RVNC股价在过去一段时间内已累积下跌超过32%,持续的下滑走势更加剧了市场对公司前景的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 抗皱剂公司Revance因撤回年度预测和推迟并购交易导致股价重挫","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVNC"],"gpt_icon":0},{"id":"2481816594","title":"BUZZ-Revance 因公司撤回年度预测、延长要约收购截止日期而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2481816594","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481816594?lang=zh_cn&edition=full","pubTime":"2024-11-08 07:29","pubTimestamp":1731022179,"startTime":"0","endTime":"0","summary":"11月7日 - ** 抗皱注射剂生产商Revance Therapeutics RVNC.O股价盘后下跌16.9%至4.80美元 ** 公司表示,鉴于其与Crown Labs的合并 ,公司将不提供任何前瞻性指导,并撤回之前提供的任何指导。** 补充说,其交易已被推迟,尚未开始 ** 皇冠和 Revance 同意将要约收购开始的最后期限延长至 2024 年 11 月 12 日。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4S3ME347:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029864427.USD","BK4588","LU1803068623.USD","LU0128525929.USD","CCK","BK4126","RVNC","LU0053671581.USD","BK4585","LU1267930573.SGD","LU0128526141.USD","LU0310800379.SGD","LU0029874061.USD","BK4007","LU0708994859.HKD","LU1892829315.USD"],"gpt_icon":0},{"id":"2480688917","title":"Revance Therapeutics, Inc.盘中异动 大幅下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480688917","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480688917?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:32","pubTimestamp":1730467975,"startTime":"0","endTime":"0","summary":"北京时间2024年11月01日21时32分,Revance Therapeutics, Inc.股票出现异动,股价大幅跳水5.08%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.06%。其相关个股中,Tc Biopharm Plc C/Wts 10/02/2028 、Klotho Neurosciences Inc C/Wts 21/06/2029 、Theriva Biologics, Inc.涨幅较大,Theriva Biologics, Inc.、Athira Pharma, Inc.、Elevai Labs, Inc.较为活跃,换手率分别为1286.72%、111.91%、75.01%,振幅较大的相关个股有Cyclerion Therapeutics, Inc.、Mesoblast Ltd、Athira Pharma, Inc.,振幅分别为19.38%、18.08%、12.57%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101213255971a3d6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101213255971a3d6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RVNC","LU0053671581.USD","BK4007","LENZ","BK4585","BK4588"],"gpt_icon":0},{"id":"2479343922","title":"BUZZ--美国股票走势-Monte Rosa、EyePoint Pharma、Shake Shack","url":"https://stock-news.laohu8.com/highlight/detail?id=2479343922","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479343922?lang=zh_cn&edition=full","pubTime":"2024-10-29 00:28","pubTimestamp":1730132923,"startTime":"0","endTime":"0","summary":" * Eikon 个股走势搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 10月28日 - 华尔街周一开盘走高,美国主要股指在经历了动荡的一周交易后有望收复部分失地,此前将有一系列大型公司发布财报,11月5日总统大选也将进入最后阶段。美东时间12:20,道琼斯工业平均指数 上涨0.68%,报42,402.47点。标普500指数 上涨0.45%,报5,834.04点;纳斯达克综合指数 上涨0.58%,报18,625.62点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ca438d53490fb5e5880a84acba8fd54e","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVX","ON","NVDA","L","AMIX","XOM","HUT","CCL","REAL","RBLX","MANU","ABBV","GLUE","COP","PRCT","3NVD.UK","HE","SHAK","TQQQ","GEHC","RVNC","AZUL","MNQmain","2NVD.UK","GLW","CDW","MSFT","SQQQ","DDM","EVOK","DOG",".IXIC","CNC","QLD","SDOW","ADT","QID","AMZN",".DJI","AAPL","EYPT",".SPX"],"gpt_icon":1},{"id":"2478489566","title":"Revance Therapeutics, Inc.股价拉升27.87% 市值涨1.75亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478489566","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478489566?lang=zh_cn&edition=full","pubTime":"2024-10-28 21:31","pubTimestamp":1730122260,"startTime":"0","endTime":"0","summary":"北京时间2024年10月28日21时31分,Revance Therapeutics, Inc.股票出现异动,股价急速拉升27.87%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。其相关个股中,Klotho Neurosciences Inc C/Wts 21/06/2029 、Monte Rosa Therapeutics, Inc.、Revance Therapeutics, Inc.涨幅较大,Tc Biopharm Plc、Viracta Therapeutics, Inc.、Immunoprecise Antibodies Ltd.较为活跃,换手率分别为540.99%、47.82%、36.02%,振幅较大的相关个股有珐博进、Precigen, Inc.、Matinas Biopharma Holdings, Inc.,振幅分别为6.49%、4.71%、4.31%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102821310095bd74dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102821310095bd74dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","LU0053671581.USD","BK4139","RVNC","BK4007","LENZ"],"gpt_icon":0},{"id":"2478103031","title":"BUZZ-Revance 因与 Teoxane 签订独家分销协议而飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2478103031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478103031?lang=zh_cn&edition=full","pubTime":"2024-10-28 18:59","pubTimestamp":1730113152,"startTime":"0","endTime":"0","summary":" 10月28日 - ** 抗皱注射剂生产商Revance Therapeutics 的股价盘前上涨20.6%至5.67美元 ** 公司称已获得 独家分销协议,将在美国进口、销售和分销 Teoxane 生产的一种皮肤填充剂** 表示今后还将在美国进口和销售 Teoxane 生产的透明质酸填充剂产品** 皮肤填充剂和透明质酸填充剂都是通过注射到皮下来改善外观的。** 8 月,Revance 同意 被私人控股的 Crown Laboratories 收购,交易价值为 9.24 亿美元。** 截至上一交易日收盘,RVNC股价累计下跌46.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVNC","BK4588","BK4585","LU0053671581.USD","BK4007"],"gpt_icon":0},{"id":"2478793636","title":"Revance Therapeutics, Inc.盘中异动 早盘急速下跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478793636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478793636?lang=zh_cn&edition=full","pubTime":"2024-10-25 21:57","pubTimestamp":1729864649,"startTime":"0","endTime":"0","summary":"北京时间2024年10月25日21时57分,Revance Therapeutics, Inc.股票出现异动,股价大幅下挫5.09%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.68%。其相关个股中,Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 、Elevai Labs, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大,180 Life Sciences Corp.、Elevai Labs, Inc.、Tc Biopharm Plc较为活跃,换手率分别为672.75%、567.87%、105.90%,振幅较大的相关个股有Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Elevai Labs, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 ,振幅分别为77.79%、64.64%、57.09%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025215729971a255e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025215729971a255e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4007","BK4585","BK4139","RVNC","LENZ","LU0053671581.USD"],"gpt_icon":0},{"id":"2470419964","title":"Revance Therapeutics, Inc.盘中异动 临近午盘股价大涨5.03%报5.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470419964","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470419964?lang=zh_cn&edition=full","pubTime":"2024-09-24 23:58","pubTimestamp":1727193506,"startTime":"0","endTime":"0","summary":"北京时间2024年09月24日23时58分,Revance Therapeutics, Inc.股票出现波动,股价快速拉升5.03%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.86%。其相关个股中,Seelos Therapeutics, Inc.、Wave Life Sciences Ltd.、Capricor Therapeutics, Inc.涨幅较大,Seelos Therapeutics, Inc.、Silexion Therapeutics Corp、Onconetix, Inc.较为活跃,换手率分别为4051.28%、183.22%、134.30%,振幅较大的相关个股有Seelos Therapeutics, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Onconetix, Inc.,振幅分别为101.84%、58.52%、45.08%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092423582798e38b12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092423582798e38b12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","BK4139","BK4007","BK4588","RVNC","LENZ","BK4585"],"gpt_icon":0},{"id":"2469186112","title":"Revance Therapeutics, Inc.股价重挫10.33% 市值跌5606.93万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2469186112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469186112?lang=zh_cn&edition=full","pubTime":"2024-09-23 21:31","pubTimestamp":1727098282,"startTime":"0","endTime":"0","summary":"北京时间2024年09月23日21时31分,Revance Therapeutics, Inc.股票出现波动,股价大幅跳水10.33%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.26%。其相关个股中,Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Pharmacyte Biotech, Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大,Black Diamond Therapeutics, Inc.、Galmed Pharmaceuticals Ltd.、Scisparc Ltd.较为活跃,换手率分别为25.57%、22.42%、22.18%,振幅较大的相关个股有Pharmacyte Biotech, Inc.、天演药业、Xtl生物制药,振幅分别为18.52%、13.14%、8.81%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409232131229f106f25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409232131229f106f25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","RVNC","BK4139","BK4007","BK4588","BK4585","LENZ"],"gpt_icon":0},{"id":"2460706735","title":"Revance Therapeutics, Inc.2024财年第二财季实现净利润-37.47百万美元,同比增加44.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460706735","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460706735?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:03","pubTimestamp":1723910629,"startTime":"0","endTime":"0","summary":"8月18日,Revance Therapeutics, Inc.公布财报,公告显示公司2024财年第二财季净利润为-37.47百万美元,同比增加44.34%;其中营业收入为65.39百万美元,同比增加12.49%,每股基本收益为-0.36美元。从资产负债表来看,Revance Therapeutics, Inc.总负债6.25亿美元,其中短期债务31.61百万美元,资产负债比为0.80,流动比率为0.04。机构评级:截至2024年8月18日,当前有7家机构对Revance Therapeutics, Inc.目标价做出预测,其中目标均价为11.71美元,其中最低目标价为6.00美元,最高目标价为25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180006029f3406e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180006029f3406e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVNC","LENZ"],"gpt_icon":0},{"id":"2459937738","title":"BUZZ--美国股票走势-Revance, B Riley, Neuronetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2459937738","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459937738?lang=zh_cn&edition=full","pubTime":"2024-08-13 02:26","pubTimestamp":1723487209,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 8月12日 - 美国股市周一在寻找方向的过程中陷入困境,投资者正在为本周的一系列经济数据做准备,他们重点关注美国消费者物价,以衡量美联储货币政策路径的前景。美东时间13:44,道琼斯工业平均指数 为!标普500指数 上涨0.01%,报5344.68点;纳斯达克综合指数 上涨0.35%,报16803.296点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXD","COHR","LU0689472784.USD","LU2756315318.SGD","LU2505996681.GBP","TJX","DLTR","LU0175139822.USD","WVE","DG","MNQmain","JBLU","SDOW","RILY","UDOW","BUZZ","DJX","KEY","LU0096364046.USD","LU2505996509.AUD","PSQ","NQmain","TQQQ","IE0009355771.USD","STIM","DOG","NVDA","HUMA","LU0820561909.HKD","QLD",".DJI","RVNC","HPE","HD","SMCI",".SPX","SQQQ","IBM","HE",".IXIC","DDM","LU0097036916.USD","LU1861558580.USD","QID","ULCC"],"gpt_icon":1},{"id":"2459377339","title":"BUZZ--美国股票走势-Revance, B Riley, Neuronetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2459377339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459377339?lang=zh_cn&edition=full","pubTime":"2024-08-13 02:26","pubTimestamp":1723487209,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 8月12日 - 美国股市周一在寻找方向的过程中陷入困境,投资者正在为本周的一系列经济数据做准备,他们重点关注美国消费者物价,以衡量美联储货币政策路径的前景。美东时间13:44,道琼斯工业平均指数 为!标普500指数 上涨0.01%,报5344.68点;纳斯达克综合指数 上涨0.35%,报16803.296点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHR","DDM","TQQQ","ULCC","HOOD","DXD","LU0096364046.USD","LU2756315318.SGD",".DJI","HE","QLD","LU0097036916.USD","RVNC","WVE","LU0820561909.HKD","NQmain","HD","RILY","LU2505996681.GBP","IBM","SQQQ","DLTR","LU1861558580.USD","DOG","HUMA",".IXIC","IE0009355771.USD",".SPX","HPE","TJX","LUMN","KEY","DJX","DG","LU0689472784.USD","PSQ","QID","BUZZ","UDOW","LLY","SDOW","CLSK","JBLU","MNQmain","LU0175139822.USD","STIM","SBUX","LU2505996509.AUD"],"gpt_icon":1},{"id":"2458498510","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2458498510","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458498510?lang=zh_cn&edition=full","pubTime":"2024-08-12 21:38","pubTimestamp":1723469928,"startTime":"0","endTime":"0","summary":" 路透8月12日 - 截至格林尼治标准时间周一 1330 时,有以下竞购、兼并、收购和处置报告: ** 抗皱注射剂生产商Revance Therapeutics 已同意被私人控股的Crown Laboratories收购,交易价值9.24亿美元,包括债务在内。** 英国竞争监督机构表示,它正在调查芯片设计软件制造商Synopsys 斥资350亿美元收购Ansys 是否会影响英国的竞争。** 英国皇家邮政母公司国际配送服务公司 宣布,其包裹服务业务GLS将把美国货运部门出售给总部位于加利福尼亚州的DC物流公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","BK4588","RVNC","LU0053671581.USD"],"gpt_icon":0},{"id":"2458985111","title":"Revance Therapeutics, Inc.盘中异动 股价大涨85.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458985111","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458985111?lang=zh_cn&edition=full","pubTime":"2024-08-12 21:31","pubTimestamp":1723469484,"startTime":"0","endTime":"0","summary":"北京时间2024年08月12日21时31分,Revance Therapeutics, Inc.股票出现波动,股价快速拉升85.55%。Revance Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.44%。Revance Therapeutics, Inc.公司简介:Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司,包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。消息层面,截至21时31分,Revance Therapeutics, Inc.股票正面舆情新闻比例33.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408122131249f248f7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408122131249f248f7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","RVNC","BK4588","BK4007","LENZ","BK4585","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revance.com","stockEarnings":[{"period":"1week","weight":-0.1038},{"period":"1month","weight":-0.2803},{"period":"3month","weight":-0.4234},{"period":"6month","weight":0.4022},{"period":"1year","weight":-0.4744},{"period":"ytd","weight":-0.5677}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revance Therapeutics, Inc.于1999年8月10日成立于特拉华公司,当时名为Essentia Biosystems公司。公司是一家处于专业临床阶段的生物制药公司,专注于开发、制造和商业化用以美容和治疗的异常型肉毒杆菌毒素产品。肉毒杆菌毒素是一种良好的蛋白,目前广泛应用于美容和治疗适应症,在美国和其他国家是一个数十亿美元的市场。目前批准和商用的肉毒杆菌毒素都是注入型的。RT001, 公司的主要候选产品,是a型肉毒毒素局部配方,相对于现有注射肉毒杆菌毒素市场产品,被认为有显著的优势。公司的第二个候选产品RT002,是一种新型注射肉毒杆菌毒素类型的配方,其设计更有针对性,与其他肉毒杆菌毒素注射产品相比,更持久。这些候选产品,结合了公司的净化肉毒杆菌毒素和专有肽输送系统。公司对其两个候选产品,在全球拥有发行权利。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.017146},{"month":2,"riseRate":0.6,"avgChangeRate":0.034292},{"month":3,"riseRate":0.363636,"avgChangeRate":0.011213},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.023839},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.009304},{"month":6,"riseRate":0.636364,"avgChangeRate":0.025437},{"month":7,"riseRate":0.272727,"avgChangeRate":0.019423},{"month":8,"riseRate":0.454545,"avgChangeRate":0.053158},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.007424},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.056267},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.035171},{"month":12,"riseRate":0.6,"avgChangeRate":0.084189}],"exchange":"NASDAQ","name":"Revance Therapeutics Inc","nameEN":"Revance Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revance Therapeutics Inc(RVNC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revance Therapeutics Inc(RVNC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revance Therapeutics Inc,RVNC,Revance Therapeutics Inc股票,Revance Therapeutics Inc股票老虎,Revance Therapeutics Inc股票老虎国际,Revance Therapeutics Inc行情,Revance Therapeutics Inc股票行情,Revance Therapeutics Inc股价,Revance Therapeutics Inc股市,Revance Therapeutics Inc股票价格,Revance Therapeutics Inc股票交易,Revance Therapeutics Inc股票购买,Revance Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revance Therapeutics Inc(RVNC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revance Therapeutics Inc(RVNC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}